Clinical Trials Logo

Clinical Trial Summary

Compassionate use of crenolanib for patients with serious life-threatening illness that have exhausted all available therapies used to treat the disease, with no other viable therapy options, who is not eligible for clinical trials. This program is designed to evaluate the requests on a patient by patient basis.

Patients must have documented evidence of a point mutation in position 842 in platelet derived growth factor receptor alpha (PDGFRA-D842V) or amplification of PDGFRA or internal tandem duplication within the FMS-like tyrosine kinase 3 (FLT3-ITD) or point mutations within the tyrosine kinase domain (TKD) of FLT3 (FLT3-TKD)


Clinical Trial Description

This program is being offered on a patient by patient basis while phase 3 studies with crenolanib are ongoing.

Institutional Review Board-/Independent Ethics Committee approval must be granted before, The experimental intervention will be administered over 28-day cycles. Compassionate use of crenolanib will be limited such that it does not interfere with the supply need for phase 3 studies.

There must be adequate understanding of the indication for the requested use. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03620318
Study type Expanded Access
Source Arog Pharmaceuticals, Inc.
Contact Vinay Jain, MD
Phone 214-593-0500
Email info@arogpharma.com
Status Available
Phase

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03135054 - Combination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITD Phase 2
Completed NCT03622541 - Using Sorafenib as a Salvage Treatment for Relapsed or Refractory Acute Myeloid Leukemia Carrying FLT3-ITD Phase 2
Recruiting NCT02156297 - Sorafenib to Treat FLT3-ITD AML
Recruiting NCT03547258 - Italian Non-Interventional Study of FLT3 Mutated AML Patients
Completed NCT03170895 - Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITD Phase 2
Enrolling by invitation NCT03642236 - Combination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AML Phase 2/Phase 3